Jurjen Versluis

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Alfons JM van den Eertwegh, Jurjen Versluis, H. Pieter van den Berg et al. · The Lancet Oncology · 2012 · 356 citations

Tumor Immunology, Urology, Medicine +9

Prehospital antibiotics in the ambulance for sepsis: a multicentre, open label, randomised trial

Nadia Alam, Erick Oskam, Patricia M. Stassen et al. · The Lancet Respiratory Medicine · 2017 · 270 citations

Open Label, Antimicrobial Stewardship, Antibiotics +8

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

Alexandros Spyridonidis, Myriam Labopin, Bipin N. Savani et al. · Bone Marrow Transplantation · 2020 · 191 citations · Full text

Hematological Malignancy, Transplantation, Mixed-phenotype Acute Leukemia +8

Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation

Jurjen Versluis, Suzan D. Pas, Hendrik J. Agteresch et al. · Blood · 2013 · 130 citations · Full text

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

Jan J. Cornelissen, Jurjen Versluis, Jakob Passweg et al. · Leukemia · 2014 · 129 citations · Full text

Hematological Malignancy, Post-remission Approaches, Medicine +9